Cauldwell C B, Lau M, Fisher D M
Department of Anesthesia, University of California, San Francisco 94143-0648.
Anesthesiology. 1994 Feb;80(2):320-5. doi: 10.1097/00000542-199402000-00012.
Mivacurium's rapid onset and short duration of action in children suggests that intramuscular administration might treat laryngospasm and facilitate tracheal intubation without producing prolonged paralysis. Accordingly, the authors measured the neuromuscular effects of intramuscular mivacurium in anesthetized infants and children.
Twenty unpremedicated infants and children (3 months to 5 yr of age) were anesthetized with nitrous oxide and halothane and permitted to breathe spontaneously. When anesthetic conditions were stable, mivacurium was injected into the quadriceps or deltoid muscle. Minute ventilation and adductor pollicis twitch tension were measured. The initial mivacurium dose was 250 micrograms/kg and was increased (to a maximum of 800 micrograms/kg, at which dose the trial was ended) or decreased according to the response of the previous patient, the goal being to bracket the dose producing 80-90% twitch depression within 5 min of drug administration.
No patient achieved > 80% twitch depression within 5 min of mivacurium administration. Peak twitch depression was 90 +/- 13% (mean +/- SD) for infants and 88 +/- 15% for children at 15.0 +/- 4.6 min and 18.4 +/- 6.4 min, respectively. Ventilatory depression (a 50% decrease in minute ventilation or a 10-mmHg increase in end-tidal carbon dioxide tension) occurred at 9.0 +/- 4.4 min in nine infants and 13.6 +/- 7.5 min in 10 children; ventilatory depression did not develop in one infant given a dose of 350 micrograms/kg. Time to peak twitch depression or ventilatory depression was not faster with larger doses.
Although ventilatory depression preceded twitch depression, both occurred later with intramuscular mivacurium than would be expected after intravenous mivacurium or intramuscular succinylcholine. The authors speculate that the onset of intramuscular mivacurium is too slow to treat laryngospasm or to facilitate routine tracheal intubation in infants or children, despite administration of large doses.
米库氯铵在儿童中起效迅速且作用持续时间短,这表明肌内注射可能治疗喉痉挛并有助于气管插管,而不会导致长时间麻痹。因此,作者测定了肌内注射米库氯铵对麻醉的婴儿和儿童的神经肌肉效应。
20名未用术前药的婴儿和儿童(3个月至5岁)用氧化亚氮和氟烷麻醉,并允许自主呼吸。当麻醉状态稳定时,将米库氯铵注入股四头肌或三角肌。测量每分通气量和拇内收肌抽搐张力。初始米库氯铵剂量为250微克/千克,并根据前一位患者的反应增加(最大至800微克/千克,达到此剂量时试验结束)或减少,目标是确定在给药后5分钟内产生80%至90%抽搐抑制的剂量范围。
在米库氯铵给药后5分钟内,没有患者的抽搐抑制率超过80%。婴儿和儿童的抽搐抑制峰值分别在15.0±4.6分钟和18.4±6.4分钟时为90±13%(平均值±标准差)和88±15%。9名婴儿在9.0±4.4分钟时出现通气抑制(每分通气量减少50%或呼气末二氧化碳分压升高10mmHg),10名儿童在13.6±7.5分钟时出现通气抑制;1名接受350微克/千克剂量的婴儿未出现通气抑制。较大剂量时,达到抽搐抑制峰值或通气抑制的时间并不更快。
虽然通气抑制先于抽搐抑制出现,但肌内注射米库氯铵时两者出现的时间均比静脉注射米库氯铵或肌内注射琥珀酰胆碱后预期的时间要晚。作者推测,尽管给予大剂量,肌内注射米库氯铵的起效太慢,无法治疗婴儿或儿童的喉痉挛或促进常规气管插管。